west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "缺氧缺血性脑病" 8 results
  • Application of Auditory Brainstem Response in the Hearing Loss and Prognosis Research on Neonatal Hypoxic Ischemic Encephalopathy

    Objective Application of auditory brainstem response (ABR) in the study on the relationship of neonates with hypoxic-ischemic encephalopathy (HIE) and the children with hearing loss and auxiliary determine the prognosis of encephalopathy. Methods We prospectively selected neonates diagnosed as HIE in the department of neonatology of the Chengdu Women and Children Central Hospital from January, 2006 to June, 2008. Neonatal ABR was tested and the prognosis of neonates were observed through 3-year followed up in order to analyze the relationship between HIE severity and the severity of hearing handicap and the relationship between the severity of hearing handicap and prognosis. Statistical analysis was performed using SPSS 18.0. χ2 test was used to compare the rate between groups. Results 40 cases involving 80 ears were included, of which 33 cases accomplished the 3-year follow-up for prognosis. The results showed that, 86.3% HIE neonates had hearing handicap (mainly mild hearing loss, 40.0%). Medium-severe HIE groups had more serious hearing handicap than Mild HIE group with a statistical significance (continuity correction χ2=7.383, P=0.007). ABR results showed that, mild HIE is mainly manifested as I wave PL prolonged or poorly differentiated, accounting for 78.1%; medium - severe HIE are mainly manifested as III and V wave PL prolonged central segment abnormalities, accounting for 95.8%; the hearing threshold no more than 60 dB group had better prognosis than the hearing threshold more than 60 dB group prognosis (Fisher exact probability P=0.001). Conclusion ABR reflects that HIE severity and was positively related to the severity of hearing handicap. The more serious hearing loss in neonates is, the worse prognosis the neonates have. ABR can be used to assist the assessment of the prognosis of neonatal HIE.

    Release date: Export PDF Favorites Scan
  • Shengmai Injection for Hypoxic-ischemic Encephalopathy: A Systematic Review

    Objective To evaluate the efficacy and safety of Shengmai injection for hypoxic-ischemic encephalopathy (HIE). Methods We searched MEDLINE (1966 to February 2007), EMBASE (1980 to February 2007), CBM (1978 to 2006), CNKI (1979 to February 2007), VIP (1989 to February 2007), and handsearched five Journals on Pediatrics. We evaluated features of quality of included studies, including randomization, blinding, allocation concealment and loss of follow-up. Meta-analyses were performed using The Cochrane Collaboration’s RevMan 4.2.8. Results Seven randomized controlled trials were included. The cure rate on day 5 in the Shengmai injection group was higher than in the control group (RR 1.55, 95%CI 1.25 to 1.93), but this rate was similar on day 10 (RR 0.74, 95%CI 0.43 to 1.29). No significant difference in cure rate was noted between the Shengmai injection group and naloxone group (RR 0.88, 95%CI 0.53 to 1.46). No significant differences were observed in mortality (RR0.44, 95%CI 0.16 to 1.19) and mutilation rate (RR 0.58, 95%CI 0.21 to 1.56) between the Shengmai injection group and the control group. For those babies suffering from HIE combined with myocardial damage, Shengmai injection could speed up the recovery of ECG (WMD=–2.02, 95%CI –2.76 to –1.28) and myocardial enzymogram (CK-MB: WMD= –4.78, 95%CI –6.77 to –2.79; CK-BB: WMD=–2.68, 95%CI –4.58 to –0.78). Significant differences in NBNA score were noted between the Shengmai injection group and the control group on day 5 (WMD=4.05, 95%CI 2.47 to 5.63) and day 10 (WMD=3.50, 95%CI 2.26 to 4.74). No fatal side effects were reported. Conclusions Shengmai injection has certain therapeutic values in treating HIE. Shengmai injection can speed up the recovery ECG, CK-BM and CK-BB of HIE patients, especially in those who have myocardial damage. Shengmai injection can also improve the NBNA score. However, because of the low statistical power and high risks for selection bias, performance bias and measurement bias in the included trials, these conclusions need to be interpreted cautiously.

    Release date:2016-09-07 02:12 Export PDF Favorites Scan
  • Fructose 1,6-Diphosphate in Hypoxic lschemic Encephalopathy:A Systematic Review

    Objective To assess the effectiveness and safety of fructose 1,6-diphosphate (FDP) in the treatment of hypoxic ischemic encephalopathy (HIE)patients. Methods Biomedical databases, including MEDLINE (1977 -2004 ), EMBASE(1989- 2004) ,Cochrane Injuries Group trials register, Cochrane Controlled Trials Register, CBMdisk and CNKI (1994- 2005 )were searched. Chnical trials were collecte&Quality assessments of chnical trials were carried out. Randomized controlled trials (RCTs) with mortality and the incidence of cerebral palsy, epilepsy and mental defect were selected for meta-analysis. Results Nine RCTs were included, and all were done in China. None of the 9 RCTs described the method of randomization or allocation concealment. None of the 9 RCTs mentioned wether blindness was use& In Jadad score, 5 trials were scored by 2 and 4 trials were 1. Seven trials were included in the meta-analysis of death, which showed that the obsolute risk (OR) [95% confidence interval (CI)] of death following FDP administration was 0. 50 (95% CI 0. 21 to 1.16). Five RCTs reported the results of follow-up. When intention to treat (ITT) analysis was adopted, the OR of FDP on cerebral palsy was 0. 36 (95% CI 0. 19 to 0. 89), on epilepsy was 0.74 (95% CI 0. 29 to 1.88), and on dementia was 0. 21 (95% CI 0. 06 to 0.70). We didn't conduct sensitivity analysis because no RCTs were of high quality. We didn't identify clinical trials compared with adverse reactions between the two groups. Conclusions The quality of RCTs on FDP for HIE is poor. Because there were no RCTs of high quality available, we can't draw a conlusion. Well-designed RCTs with economic evaluation are urgently needed to evaluate the value of FDP in the treatment of HIE.

    Release date:2016-09-07 02:26 Export PDF Favorites Scan
  • The Relationship among Neonatal Hypoxicischemic Encephalopathy Graduation and Intracranial Hemorrhage and Evaluation the Prognosis by Computer Tomography

    目的:通过CT影像资料评价新生儿缺氧缺血性脑病与颅内出血量的关系及其预后。方法:收集1998~2006年临床诊断为缺氧缺血性脑病70例新生儿患者的CT资料,观察CT图像显示的脑出血量,分析不同程度的缺氧缺血性脑病和出血部位与颅内出血量和预后的关系。结果:新生儿缺氧后轻、中度出血在1~2周内均可完全吸收,发生在基底节或大脑白质区域的重度出血预后较差。结论:颅内出血量与窒息缺氧程度呈正相关;发生在不同部位的出血,其预后不同。

    Release date:2016-09-08 10:02 Export PDF Favorites Scan
  • CT Findings and Clinical Analysis of Neonatal Hypoxic Ischemic Encephalopathy

    摘要:目的:探讨新生儿缺氧缺血性脑病(HIE)的CT表现与临床分析。方法:对54例HIE患儿的CT表现及临床特点进行回顾性分析。结果:本组临床分度为轻度21例,占38.9%(21/54);中度24例,占44.4%(24/54);重度9例,占16.7%(9/54)。CT分度为轻度25例,占46.3%(25/54);中度18例,占33.3%(18/54);重度11例,占20.4%(11/54)。结论:CT对明确HIE的范围、动态观察病情变化,对临床早期干预治疗,降低后遗症有积极作用。Abstract: Objective: To explore the neonatal hypoxic ischemic encephalopathy (HIE) of CT findings and clinical analysis.Methods:Children of the 54 cases of HIE and clinical performance characteristics of CT were retrospectively analyzed.Results:Clinical subgroup 21 cases of mild degree, accounting for 38.9% (21/54); 24 cases of moderate, accounting for 44.4% (24/54); 9 cases of severe, accounting for 16.7% (9 / 54). CT at 25 cases of mild degree, accounting for 46.3% (25/54); 18 cases of moderate, accounting for 33.3% (18/54); 11 cases of severe, accounting for 20.4% (11/54).Conclusion:CT of the scope of HIE clear, dynamic observation of the disease changes in the clinical treatment of early intervention to reduce the aftereffects have a positive effect.

    Release date:2016-09-08 10:12 Export PDF Favorites Scan
  • Evaluation of Clinical Grading for Neonates with Hypoxic-ischemic Encephalopathy by Diffusion Weighted Imaging

    ObjectiveTo discuss the evaluation of clinical grading for neonates with hypoxic-ischemic encephalopathy (HIE) by diffusion weighted imaging (DWI). MethodsWe retrospectively analyzed the DWI findings of 39 neonates with HIE diagnosed by clinical criteria from December 2009 to July 2013. Abnormal signals were observed for 23 neonates (59%). These neonates were divided into three groups (group A, B and C) according to the shape and range of abnormal signals. Then Kappa test was performed between groups of different clinical grading (light, medium, severe). ResultsFor groups arranged based on abnormal signals and clinical grading, the Kappa value of the consistency test was 0.797 (P < 0.001). ConclusionsDWI negativity cannot exclude the existence of HIE. However, when abnormal signals occur, we can infer the severity in neonates with HIE according to the shape and range of abnormal signals by DWI.

    Release date: Export PDF Favorites Scan
  • Treatment of Naloxone for Moderate and Severe Neonatal Hypoxia-ischemic Encephalopathy:A Meta-analysis

    ObjectiveTo objectively evaluate the effect and safety of naloxone for the treatment of moderate and severe neonatal hypoxia-ischemic encephalopathy (HIE). MethodsResearch articles published from inception to June 2015 on Cochrane library, PubMed, Web of science, Chinese Science and Technology Journal Full-text Database, Digital Full-text Journal Database and Chinese Journal Full-text Database were searched, which were relevant to naloxone in the treatment of moderate and severe neonatal HIE. And two authors extracted information via standardized data extraction form and assessed the quality of included studies independently. RevMan 5.2 software was used for Meta-analysis. ResultsAt last, 20 randomized controlled trials (involving 1 519 neonates; 783 in the treatment group and 736 in the control group) were included. The results of meta-analysis showed that the effect of naloxone for moderate and severe HIE was significantly superior to the control group[OR=5.07, 95%CI (3.61, 7.12), P < 0.000 01]. The neurobehavioral scores in neonates treated by naloxone after 5, 7, 10, and 14 days were higher than those in the control group[WMD=6.61 points, 95%CI (5.70, 7.51) points, P < 0.000 01; WMD=4.27 points, 95%CI (2.63, 5.91) points, P < 0.000 01; WMD=2.40 points, 95%CI (1.47, 3.34) points, P < 0.000 01; WMD=2.58 points, 95%CI (1.00, 4.16) points, P=0.001], respectively; while the neurobehavioral scores after 3-day treatment between the two groups had no statistically difference[WMD=0.00 points, 95%CI(-0.76, 0.77) points, P=0.99]. What's more, the disappeared time of clinical symptoms and signs (breathing improvement time, recovery time, convulsions disappearance time, and signs disappearance time) in naloxone group was superior to the control groups[WMD=-3.78 hours, 95%CI (-6.93, -0.64) hours, P=0.02; WMD=-9.66 hours, 95%CI (-14.25, -5.06) hours, P < 0.001; WMD=-2.81 hours, 95%CI (-5.28, -0.35) hours, P=0.03; WMD=-1.02 days, 95%CI (-1.84, -0.20) days, P=0.01], respectively. ConclusionsNaloxone has certain therapeutic on moderate and severe HIE. Further high-quality randomized controlled trials should be carried out to provide more reliable evidence.

    Release date: Export PDF Favorites Scan
  • EFFECT OF INTEGRIN β8 ON NEURONAL APOPTOSIS AFTER HYPOXIA ISCHEMIA IN ASTROCYTE/NEURON CO-CULTURE SYSTEM

    ObjectiveTo observe the effect of integrin β8 on the neuronal apoptosis after hypoxia ischemia (HI) in astrocyte/neuron co-culture system. MethodsAstrocytes and neurons were cultured in vitro from cerebral cortex of the P1-3 days Sprague Dawley rats and E16 days fetal rats, respectively. Immunocytochemistry staining was used to identify the purity of cells. Integrin β8 mRNA expression was qualified in the astrocytes at 12 hours, 1 day, and 2 days after HI and reoxygenation (experimental group) and in normal astrocytes (control group) by RT-PCR. Integrin β8 small interering RNA (siRNA) system was established to specifically block astrocyte β8 expression, the efficiency of integrin β8 inhibition was detected by real-time fluorescent PCR. The astrocytes and neurons were co-cultured to established the astrocyte/neuron co-culture system. The neuronal apoptosis was detected with TUNEL in the normal neurons/astrocytes group (co-cultured HI group), the astrocytes infected by integrin β8 siRNA for 2 days/normal neurons group (β8 RNA interference group), and normal neurons in vitro with HI treatment group (HI group) at 1 day after HI and reoxygenation. The normal neurons without treatment as control (control group). ResultsGlial fibrillary acidic protein and neuronal nuclei staining suggested a purity of more than 90% in cultured cells. HI resulted in an increase of integrin β8 mRNA expression at 12 hours after reoxygenation in astrocytes, which peaked at 1 day after reoxygenation, then slowly decreased and remained higher at 2 days, showing significant differences between control group and experimental group and among different time points in experimental group (P<0.05). RNA interference efficiency was most significant at 2 days after astrocytes infected with integrin β8 siRNA (P<0.05). The neuronal apoptosis was significantly increased in HI group, co-cultured HI group, and β8 RNA interference group when compared with control group (P<0.05). But neuronal apoptosis index (AI) was significantly decreased in co-cultured HI group and β8 RNA interference group when compared with HI group (P<0.05). The significant difference of AI was found between co-cultured HI group and β8 RNA interference group (P<0.05). ConclusionIntegrin β8 expression can be induced with hypoxic-ischemic brain damage, leading to decreased AI of neurons and obvious protective effect.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content